HilleVax, Inc.
HLVXDelisted Sep 17, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001888012
HilleVax, Inc. was delisted on Sep 17, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 74 institutions reported holding it in 13F filings for Q2 2025, worth $82.5M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 74
- Q2 2025, −7 vs. previous quarter
- 13F value
- $82.5M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding HLVX, Q2 2025
No superinvestor reported holding HLVX at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by HilleVax, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 (view filing) | Feb 4-11 | 8 daysLate | Hershberg RobertSee Remarks | SSale | −26.5K | $1.83 | −$48.6K | −2.4%1.10M after | 2 lots |
| Feb 12, 2025 (view filing) | Feb 4-11 | 8 daysLate | Maltbie ShaneChief Financial Officer | SSale | −8.29K | $1.82 | −$15.1K | −9.4%79.9K after | 2 lots |
| May 22, 2024 (view filing) | May 20-22 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $14.80 | −$266.3K | −2.3%764.9K after | 3 lots10b5-1 |
| May 3, 2024 (view filing) | May 1-3 | 2 days | Kohli AdityaDirector | SSale | −6.90K | $14.03 | −$96.7K | −0.9%782.9K after | 3 lots10b5-1 |
| Apr 5, 2024 (view filing) | Apr 3-5 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $14.69 | −$264.5K | −2.2%789.8K after | 3 lots10b5-1 |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | McLoughlin SeanChief Operating Officer | PPurchase | +1.25K | $16.98 | +$21.2K | New position1.25K after | |
| Mar 20, 2024 (view filing) | Mar 18-20 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $54,752.03 | −$985.5M | −2.2%807.8K after | 3 lots10b5-1Price outlier |
| Mar 8, 2024 (view filing) | Mar 6-8 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $18.66 | −$335.9K | −2.1%825.8K after | 3 lots10b5-1 |
| Feb 22, 2024 (view filing) | Feb 20-22 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $14.95 | −$269.1K | −2.1%843.8K after | 3 lots10b5-1 |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Kohli AdityaDirector | SSale | −6.00K | $15.32 | −$91.9K | −0.7%861.8K after | 10b5-1 |
Top 10 13F holders, Q2 2025
The largest institutional positions in HilleVax, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10,617,062 | $21.1M | 0.84% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 6,724,000 | $13.4M | 68.43% | 00.0% | Unchanged |
| Tang Capital Management LLC | 4,920,000 | $9.79M | 0.49% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 2,420,243 | $4.82M | 0.29% | +2,420,243 | New |
| Lightspeed Management Company, L.L.C. | 2,303,871 | $4.58M | 1.92% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,953,642 | $3.89M | 0.00% | −3,977−0.2% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 1,882,654 | $3.75M | 0.07% | 00.0% | Unchanged |
| Carlyle Group Inc. | 1,838,486 | $3.59M | 0.07% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,451,205 | $2.89M | 0.00% | −134,463−8.5% | Reduced |
| Balyasny Asset Management LLC | 976,297 | $1.94M | 0.00% | −26,520−2.6% | Reduced |